Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

FORM 8-K

 

---

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): November 29, 2016

 

---

 

Novelion Therapeutics Inc.

(Exact Name of Registrant as specified in its charter)

 

---

 

British Columbia, Canada		000-17082		N/A
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

887 Great Northern Way, Suite 250, Vancouver, B.C.

Canada, V5T 4T5

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: [phone]

 

Not Applicable

(Registrant’s name or former address, if change since last report)

 

---

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨                  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨                  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨                  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

Item 8.01. Other Events.

 

On November 29, 2016, QLT Inc. (“QLT”) and Aegerion Pharmaceuticals, Inc. (“Aegerion”) issued a joint press release announcing that they completed the transactions contemplated by the Agreement and Plan of Merger, dated as of June 14, 2016 (as amended), among QLT, Aegerion and Isotope Acquisition Corp., an indirect wholly-owned subsidiary of QLT.  In connection with the transactions, QLT changed its name to “Novelion Therapeutics Inc.”  A copy of the joint press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

 

2

---

 

Item 9.01.           Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1

Joint Press Release dated November 29, 2016

 

3

---

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	NOVELION THERAPEUTICS INC.
	By:	/s/ Ben Harshbarger
	Name:	Ben Harshbarger
	Title:	General Counsel

 

Date: November 29, 2016

 

4

---